Endo, Impax Can't Trim Opana Pay-For-Delay MDL, Class Says
End-payors fought to keep alive state antitrust claims in litigation accusing pharmaceutical giants Endo and Impax of a pay-for-delay scheme involving opioid pain drug Opana ER, telling an Illinois federal judge...To view the full article, register now.
Already a subscriber? Click here to view full article